HEALTH AND ECONOMIC IMPACT OF CATCH-UP RSV MAB IMMUNIZATION IN INFANTS IN GREECE
Author(s)
Ilias Gountas1, Georgios Trimis, PhD2, ANASTASIOS SKROUMPELOS, PhD3, Eleni Boutselakou, MD3, Dzhumber Ugrekhelidze, PharmD, PhD4, Eleana Tsoumani, PhD5, Klodeta Kura, PhD6, Antonis Karokis, PhD2.
1Market access manager, MSD, Alimos, Greece, 2MSD, Alimos, Greece, 3MSD, Athens, Greece, 4MSD Switzerland, Horgen, Switzerland, 5MSD, Hoddesdon, Hertfortshire, United Kingdom, 6MSD, London, United Kingdom.
1Market access manager, MSD, Alimos, Greece, 2MSD, Alimos, Greece, 3MSD, Athens, Greece, 4MSD Switzerland, Horgen, Switzerland, 5MSD, Hoddesdon, Hertfortshire, United Kingdom, 6MSD, London, United Kingdom.
OBJECTIVES: Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization. In Greece, RSV interventions—maternal vaccination (MV) and monoclonal antibody (mAb) prophylaxis—are currently recommended only for infants born during the RSV season (November-March), with no catch-up programme for those born before season onset. This policy restricts access for a substantial proportion of infants entering their first RSV season. This study evaluated the health and economic impact of introducing catch-up RSV mAb intervention for all infants entering their first RSV season.
METHODS: A decision-analytic model was adapted to estimate the impact of catch-up RSV mAb intervention in Greece from a societal perspective with a 12-month post-mAb-administration time horizon using a €51,000 willingness-to-pay threshold. Four scenarios were evaluated: (1) current practice (CP): 35% MV coverage (~11,500 infants) and 20% mAb coverage among eligible infants (~5,000 infants); (2) catch-up mAb eligibility extended to infants <3 months (~9,300 infants); (3) catch-up extended to infants <8 months (~15,000 infants); and (4) catch-up extended to infants <8 months with 90% RSV coverage (~50,000 infants). Maternal vaccination remained constant at 11,500 infants across all scenarios, as only infants born during the RSV season were covered through maternal immunization. Intervention acquisition costs, healthcare resource and societal costs use were sourced from literature and public databases.
RESULTS: Compared with CP, catch-up intervention yielded an additional 18, 47, and 253 QALYs in scenarios 2, 3, and 4, respectively, with incremental costs of €0.74 million, €2.31 million, and €8.26 million. Corresponding ICERs were €40,790, €49,025, and €32,746 per QALY gained. Under scenario 4, an estimated 1,846 hospitalizations, 2,889 emergency department visits, and 4,112 outpatient visits would be averted compared with CP.
CONCLUSIONS: Introducing RSV catch-up immunization in Greece is a cost-effective strategy that could prevent a substantial number of RSV-related complications, with greater health and economic benefits achieved at higher immunization coverage.
METHODS: A decision-analytic model was adapted to estimate the impact of catch-up RSV mAb intervention in Greece from a societal perspective with a 12-month post-mAb-administration time horizon using a €51,000 willingness-to-pay threshold. Four scenarios were evaluated: (1) current practice (CP): 35% MV coverage (~11,500 infants) and 20% mAb coverage among eligible infants (~5,000 infants); (2) catch-up mAb eligibility extended to infants <3 months (~9,300 infants); (3) catch-up extended to infants <8 months (~15,000 infants); and (4) catch-up extended to infants <8 months with 90% RSV coverage (~50,000 infants). Maternal vaccination remained constant at 11,500 infants across all scenarios, as only infants born during the RSV season were covered through maternal immunization. Intervention acquisition costs, healthcare resource and societal costs use were sourced from literature and public databases.
RESULTS: Compared with CP, catch-up intervention yielded an additional 18, 47, and 253 QALYs in scenarios 2, 3, and 4, respectively, with incremental costs of €0.74 million, €2.31 million, and €8.26 million. Corresponding ICERs were €40,790, €49,025, and €32,746 per QALY gained. Under scenario 4, an estimated 1,846 hospitalizations, 2,889 emergency department visits, and 4,112 outpatient visits would be averted compared with CP.
CONCLUSIONS: Introducing RSV catch-up immunization in Greece is a cost-effective strategy that could prevent a substantial number of RSV-related complications, with greater health and economic benefits achieved at higher immunization coverage.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH188
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Public Health
Disease
Pediatrics, Vaccines